Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 3 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
NovMetaPharma Co., Ltd. is currently navigating 4 pending office actions within the Biotechnology & Pharmaceuticals technology area. The prosecution workload is distributed across 4 distinct examiners, which suggests that each pending matter is being handled by a different individual. This distribution indicates a lack of examiner concentration, requiring the company to adapt to the specific styles of 4 distinct examiners simultaneously.
The portfolio spans 3 distinct art units, showing that the company's intellectual property interests in Biotechnology & Pharmaceuticals are spread across several specialized groups within the patent office. This variety of 3 distinct art units may introduce different procedural norms for the 4 pending office actions. KRINOS, EMILY LYNN is identified as the busiest examiner for this portfolio, currently overseeing 1 busiest examiner pending action.
Since the busiest examiner handles only 1 of the total pending actions, the company faces a fragmented prosecution environment where no single examiner holds a majority of the active cases. This requires a strategy that addresses the unique requirements of the examiners and art units involved.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (25%) |
| Double-patenting + other | 1 (25%) |
| Multi-statute (no §101) | 2 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KRINOS, EMILY LYNN | 1 | — | — |
| SIMMONS, CHRIS E | 1 | 34.1% | +19.4% |
| MOSELEY II, NELSON B | 1 | 68.0% | +41.5% |
| ESPINOSA, CLAUDIA EDILMA | 1 | 50.9% | +57.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19107159 | USE OF COMPOSITION CONTAINING ZINC SALT AND CYCLO-HISPRO FOR PREVENTION, ALLEVIATION OR TREATMENT OF RESPIRATORY DISEASE | KRINOS, EMILY LYNN | — |
| 18204520 | COMPOSITION AND METHOD FOR TREATING CANCER | MOSELEY II, NELSON B | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17406626 | METHOD FOR TREATING INFLAMMATORY BOWEL DISEASES | ESPINOSA, CLAUDIA EDILMA | 18d overdue |
| 18385686 | METHOD FOR TREATMENT OF CYTOKINE RELEASE SYNDROME | SIMMONS, CHRIS E | — |
| 18204520 | COMPOSITION AND METHOD FOR TREATING CANCER | MOSELEY II, NELSON B | — |
| Art Unit | Apps |
|---|---|
| 1629 | 1 |
| 1642 | 1 |
| 1654 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19107159 | USE OF COMPOSITION CONTAINING ZINC SALT AND CYCLO-HISPRO FOR PREVENTION, ALLEVIATION OR TREATMENT OF RESPIRATORY DISEASE | KRINOS, EMILY LYNN | — | §102§112 | Non-Final OA | — | Pending | Feb 27, 2025 |
| 18385686 | METHOD FOR TREATMENT OF CYTOKINE RELEASE SYNDROME | SIMMONS, CHRIS E | 1629 | §102§112DP | Non-Final OA | — | Pending | Oct 31, 2023 |
| 18204520 | COMPOSITION AND METHOD FOR TREATING CANCER | MOSELEY II, NELSON B | 1642 | §103§112 | Non-Final OA | — | Pending | Jun 01, 2023 |
| 17406626 | METHOD FOR TREATING INFLAMMATORY BOWEL DISEASES | ESPINOSA, CLAUDIA EDILMA | 1654 | §103 | Final Rejection | 18d overdue | Pending | Aug 19, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial